Thus, there is a pressing need to further our knowledge of the molecular bases that limit the response to trastuzumab in order to discover predictive biomarkers, overcome resistance to standard anti-HER2 treatment by developing alternative therapies, and eventually enhance treatment response and survival for HER2-positive breast-cancer patients [3,5]. The gene discussed is ERBB2; the disease is breast carcinoma.